Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term phase 3 study of BIVV001 prophylaxis in previously treated patients with severe hemophilia A
NL-OMON54275Phase 3Recruiting
- Sponsor
- Sanofi
- Start
- Oct 2021
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of efanesoctocog alfa in hemophilia A (2 arms), sponsored by Sanofi. Primary endpoint: Occurrence of inhibitor development. Started Oct 2021; status: recruiting.
02
Drugs
efanesoctocog alfa
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NL-OMON54275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54275.